⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 22, 2024Diabetes CareOpen Access

Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT

Ildiko Lingvay John Deanfield Steven E. Kahn Peter Weeke Hermann Toplak Benjamin M. Scirica Lars Rydén Naveen Rathor Jorge Plutzky Cristóbal Morales A. Michael Lincoff Michael Lehrke Ole Kleist Jeppesen Grzegorz Gajos Helen M. Colhoun Bertrand Cariou Donna H. Ryan

View Full Paper

Ask AI

Bookmark

Share

Abstract

To evaluate the cardiovascular effects of semaglutide by baseline glycated hemoglobin (HbA1c) and change in HbA1c in a prespecified analysis of Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lingvay et al. (2024) studied this question.

synapsesocial.com/papers/68e63aecb6db6435875ccbef https://doi.org/10.2337/dc24-0764

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Semaglutide and Cardiovascular Outcomes by Baseline and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT2024
2Semaglutide and Cardiovascular Outcomes by Baseline and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT2024
3Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial2024 · 86 citations
4Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial2024 · 342 citations
5Forecasting cardiovascular risk reduction with semaglutide in overweight and obese with heart disease: a nationwide cohort study2024 · 1 citations